C. Chandra Kumar
Department of Tumor Biology
Schering-Plough Research Institute
Kenilworth
NJ 07033
USA
Name/email consistency: high
- AKT crystal structure and AKT-specific inhibitors. Kumar, C.C., Madison, V. Oncogene (2005)
- Integrin alpha v beta 3 as a therapeutic target for blocking tumor-induced angiogenesis. Kumar, C.C. Curr. Drug. Targets (2003)
- Inhibition of angiogenesis and tumor growth by SCH221153, a dual alpha(v)beta3 and alpha(v)beta5 integrin receptor antagonist. Kumar, C.C., Malkowski, M., Yin, Z., Tanghetti, E., Yaremko, B., Nechuta, T., Varner, J., Liu, M., Smith, E.M., Neustadt, B., Presta, M., Armstrong, L. Cancer Res. (2001)
- Expression, purification, characterization and homology modeling of active Akt/PKB, a key enzyme involved in cell survival signaling. Kumar, C.C., Diao, R., Yin, Z., Liu, Y., Samatar, A.A., Madison, V., Xiao, L. Biochim. Biophys. Acta (2001)
- Drugs targeted against protein kinases. Kumar, C.C., Madison, V. Expert. Opin. Emerg. Drugs (2001)
- SCH 51344, an inhibitor of RAS/RAC-mediated cell morphology pathway. Kumar, C.C., Ohashi, K., Nagata, K., Walsh, A., Bar-Sagi, D., Mizuno, K. Ann. N. Y. Acad. Sci. (1999)
- Chloramine T-induced structural and biochemical changes in echistatin. Kumar, C.C., Nie, H., Armstrong, L., Zhang, R., Vijay-Kumar, S., Tsarbopoulos, A. FEBS Lett. (1998)
